Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15538067 | 0.98 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14671190 | 0.93 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL323068 | 0.88 | USP2 (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4023446 | 0.88 | KDM4E (0.32) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14391226 | 0.82 | NPSR1 (0.37) | USP2ALDH1A1LMNATSHR | |
| SCHEMBL15578278 | 0.80 | USP2 (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1672554 | 0.80 | ALDH1A1 (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL18632473 | 0.79 | CA2 (0.34) | — | |
| SCHEMBL15353749 | 0.77 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL799912 | 0.77 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981095-B2 | Intermediate compounds and process for the preparation of lurasidone and salts thereof | MAPI PHARMA LTD. (IL) | 2015-03-17 | — | — | US | disclosed |
| US-20140179922-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF | MAPI PHARMA LTD. (IL) | 2014-06-26 | — | — | US | disclosed |
| EP-2736905-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF | Mapi Pharma Limited (IL) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013014665-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF | MAPI PHARMA LTD. (IL) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011136384-A1 | A PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179922-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF | REN, AVPR1B, AVPR2 | KDM4E 3834/4885USP2 3973/4885ALDH1A1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.